kras mutation and glutathion JCI Uncovering new therapeutic targets for
Uncovering new therapeutic targets for a common KRAS mutation behind cancer KRAS mutation shown to promote tumor evasion of innate immune surveillance in lung cancer Overcoming resistance to drugs targeting KRASG12C mutation KRAS targeted therapies in cancer: novel approaches and overcoming resistance BMJ Oncology
Pay in 4 interest-free payments of $7.10 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13



